Qianjiang Yongan Pharmaceutical Co., Ltd. (SHE:002365)
China flag China · Delayed Price · Currency is CNY
14.86
+0.05 (0.34%)
Feb 4, 2026, 3:04 PM CST

SHE:002365 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Jan '23 Jan '22 Dec '20
Operating Revenue
791.78833.34959.371,4261,5461,166
Other Revenue
5.475.4713.5236.5719.546.87
797.25838.81972.891,4621,5651,173
Revenue Growth (YoY)
1.07%-13.78%-33.48%-6.58%33.47%-14.42%
Cost of Revenue
679.67672.79722.37991.131,212820.06
Gross Profit
117.57166.02250.52471.32353.73352.8
Selling, General & Admin
75.7880.61176.42249.77154.58166.85
Research & Development
32.6836.9741.540.4553.0446.66
Other Operating Expenses
14.819.1610.0913.6611.5810.09
Operating Expenses
122126.05226.39301.41228.94225.14
Operating Income
-4.4239.9724.12169.91124.79127.66
Interest Expense
-0.92-0.59-0.37-0.66-2.44-1.2
Interest & Investment Income
36.9840.7827.3912.6224.225.99
Currency Exchange Gain (Loss)
9.179.175.6421.55-4.09-8.54
Other Non Operating Income (Expenses)
-5.18-1.02-0.43-0.64-0.7-0.51
EBT Excluding Unusual Items
35.6288.3256.35202.77141.76143.39
Impairment of Goodwill
-0.52-0.52-8.25---
Gain (Loss) on Sale of Investments
4.024.43-34.55-30.34-0.28-1.19
Gain (Loss) on Sale of Assets
0.970.1945.02-0.380.25-0.01
Asset Writedown
-16.02-15.36-42.06-3.65-3.02-15.45
Legal Settlements
-10.02-10.02-23.3-22.73-13.61-4.94
Other Unusual Items
6.23.8212.847.44.758.78
Pretax Income
20.2670.866.05153.06129.85130.58
Income Tax Expense
3.0111.1534.4720.3410.8111.92
Earnings From Continuing Operations
17.2559.71-28.41132.72119.05118.66
Minority Interest in Earnings
8.162.0616.17.63-7.63-13.1
Net Income
25.4161.77-12.31140.35111.42105.56
Preferred Dividends & Other Adjustments
---0.193.63-
Net Income to Common
25.4161.77-12.31140.16107.78105.56
Net Income Growth
715.62%--25.97%5.55%17.38%
Shares Outstanding (Basic)
290293295294287288
Shares Outstanding (Diluted)
291295295294287289
Shares Change (YoY)
-0.95%-0.13%2.66%-0.63%0.06%
EPS (Basic)
0.090.21-0.040.480.380.37
EPS (Diluted)
0.090.21-0.040.480.380.37
EPS Growth
724.77%--26.66%2.75%17.69%
Free Cash Flow
38.75-12.33100.46238.2138.76102.25
Free Cash Flow Per Share
0.13-0.040.340.810.140.35
Dividend Per Share
0.1000.1000.1000.100-0.100
Dividend Growth
------33.33%
Gross Margin
14.75%19.79%25.75%32.23%22.60%30.08%
Operating Margin
-0.56%4.76%2.48%11.62%7.97%10.88%
Profit Margin
3.19%7.36%-1.27%9.58%6.88%9.00%
Free Cash Flow Margin
4.86%-1.47%10.32%16.29%2.48%8.72%
EBITDA
91.37152.65159.3293.53240.75240.72
EBITDA Margin
11.46%18.20%16.37%20.07%15.38%20.52%
D&A For EBITDA
95.79112.68135.18123.62115.96113.07
EBIT
-4.4239.9724.12169.91124.79127.66
EBIT Margin
-0.56%4.76%2.48%11.62%7.97%10.88%
Effective Tax Rate
14.84%15.74%569.54%13.29%8.32%9.13%
Revenue as Reported
797.25838.81972.891,4621,5651,173
Source: S&P Global Market Intelligence. Standard template. Financial Sources.